Be invited to scroll down for detailed information regarding the Evotec SE share, ranging from basic share data to our dividend policy.
Stock information
Basic share data
Security identification numbers:
Frankfurt Stock Exchange
(ordinary bearer shares)
ISIN: DE0005664809
OTC Markets, OTCBB
(American Depositary Shares, ADSs)
CUSIP: 30050E105
ISIN: US30050E1055
Ticker symbol:
Frankfurt Stock Exchange: EVT
OTC Markets, OTCBB: EVTCY
Bloomberg Xetra: EVT GY Equity
Bloomberg OTC Markets, OTCBB: EVTCY US Equity
Reuters Xetra: EVTG.DE
Stock exchange:
Frankfurt Stock Exchange
OTC Markets, OTCBB
Segment:
Prime Standard
Index:
MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX
Designated sponsor:
ODDO SEYDLER BANK AG
Paying agent:
Deutsche Bank AG, Frankfurt am Main
Number of shares issued:
164,574,681 ordinary bearer shares
Nominal capital:
€ 164,574,681
Security identification numbers: Frankfurt Stock Exchange (ordinary bearer shares) ISIN: DE0005664809 OTC Markets, OTCBB (American Depositary Shares, ADSs) CUSIP: 30050E105 ISIN: US30050E1055 |
|
Ticker symbol: Bloomberg Xetra: EVT GY Equity Bloomberg OTC Markets, OTCBB: EVTCY US Equity |
|
Stock exchange: |
|
Segment: |
|
Index: |
|
Designated sponsor: |
|
Paying agent: |
|
|
Number of shares issued: |
|
|
Nominal capital: |
Share Price Summary 2020 (XETRA)
High (28 December):
€ 30.30
Low (12 March):
€ 18.69
€ 18.69
Opening Price:
€ 23.79
€ 23.79
Closing Price:
€ 30.28
€ 30.28
Weighted average number of shares outstanding:
153,752,241
153,752,241
Total number of shares outstanding as at 31 Dec:
163,914,741
163,914,741
Average daily trading volume (all exchanges):
1,466,481
1,466,481
Market capitalisation as at 31 Dec:
€ 4,963.34 m
€ 4,963.34 m
Earnings per share (diluted/basic):
€ 0.04/€ 0.04
€ 0.04/€ 0.04
Dividend per share:
€ 0.00
€ 0.00
High (28 December): € 30.30 |
|
| Low (12 March): € 18.69 |
|
| Opening Price: € 23.79 |
|
| Closing Price: € 30.28 |
|
| Weighted average number of shares outstanding: 153,752,241 |
|
| Total number of shares outstanding as at 31 Dec: 163,914,741 |
|
| Average daily trading volume (all exchanges): 1,466,481 |
|
| Market capitalisation as at 31 Dec: € 4,963.34 m |
|
| Earnings per share (diluted/basic): € 0.04/€ 0.04 |
|
| Dividend per share: € 0.00 |
Stock Price & Chart
Shareholder structure
On 30 April 2021, the number of total voting rights amounts to 164,574,681.
Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec SE whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found at dgap.de.
Four major shareholders, Novo Holdings A/S, T. Rowe Price Group, Inc., Mubadala Investment Company, and ROI Verwaltungsgesellschaft mbH/Roland Oetker, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 67% according to our estimates (Evotec: 04|2021).
Shareholder structure (in %)*
* Rounding differences may occur.
Financial analysts
Overview of analysts covering the Evotec share
Baader Bank
Bruno Bulic
Citigroup Inc.
Peter Verdult
Deutsche Bank
Falko Friedrichs
EQUI.TS GmbH
Thomas Schiessle
FMR Frankfurt Main Research
Dr Mohamad Vaseghi
goetzpartners securities Limited
Kieron Banerjee
Intron Health
Naresh Chouhan
Kempen & Co. N.V.
Alexandru Cogut
Mainfirst Bank AG
Dr Marcus Wieprecht
Royal Bank of Canada (RBC)
Charles Weston
Rx Securities
Dr Samir Devani
Warburg Research
Dr Christian Ehmann
Baader Bank
Bruno Bulic
Citigroup Inc.
Peter Verdult
Deutsche Bank
Falko Friedrichs
EQUI.TS GmbH
Thomas Schiessle
FMR Frankfurt Main Research
Dr Mohamad Vaseghi
goetzpartners securities Limited
Kieron Banerjee
Intron Health
Naresh Chouhan
Kempen & Co. N.V.
Alexandru Cogut
Mainfirst Bank AG
Dr Marcus Wieprecht
Royal Bank of Canada (RBC)
Charles Weston
Rx Securities
Dr Samir Devani
Warburg Research
Dr Christian Ehmann
Important note:
Evotec is monitored and assessed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Evotec’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Evotec or its management. Evotec does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Evotec has no obligation to update or supplement the above information and makes no representation or warranty as to the accuracy and completeness of this list.
Copies of the research reports of the above-named analysts must be obtained directly from the analysts or their employers. Evotec is not able to publish the research reports due to legal considerations.
Initial public offering information*
- Segment: Neuer Markt, Frankfurt Stock Exchange
- Offering structure: Public Offering in Germany, Private placement outside Germany, Rule 144A offering in the USA
- Offer shares: 4,927,500 Offer shares each with an imputed share in the capital stock of € 1.00 per share, of which:
4,100,000 New shares issued from a capital increase
182,500 Shares sold by the selling shareholder
645,00 Over-Allotment option from a capital increase - Global coordinators: UBS Warburg AG, Deutsche Bank AG
- Further managers: SG Investment Banking, Sal. Oppenheim, Hamburger Sparkasse
- Bookbuilding period: 02 November 1999 - 08 November 1999
- Offering price: € 13.00
- Listing: 10 November 1999
- Opening price: € 24.00
- Subscribed capital: € 12,078,000
*All data not adjusted for stock split of 18 August 2000
Dividend
The payment of dividends depends on Evotec’s financial situation and liquidity requirements, general market conditions, and statutory, tax and regulatory requirements. Evotec currently intends to retain any potential future profits and reinvest them in the Company’s growth strategy to even better advance long-term growth and sustainability. In addition, Evotec SE will not be authorised to pay dividends before its annual profits exceed the losses carried forward. Evotec SE does not generate any distributable profits currently.
Contact us
Gabriele Hansen
SVP, Head of Global Corporate Communications & Marketing
T +49 40 560 81 255 F +49 40 560 81 333 investorrelations@evotec.com vCardVolker Braun
SVP, Head of Global Investor Relations & ESG
T +49 40 560 81 775 F +49 40 560 81 333 investorrelations@evotec.com vCardAnja Ben Lekhal
Investor Relations Associate
T + 49 40 56081 210 F +49 40 56081 222 investorrelations@evotec.com vCard
TOP